umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045Artikel i tidskrift (Refereegranskat) Epub ahead of print
Abstract [en]

Background: Taxane treatment may be a suitable therapeutic option for patients with castration‐resistant prostate cancer and high expression of constitutively active androgen receptor variants (AR‐Vs). The aim of the study was to compare the effects of cabazitaxel and androgen deprivation treatments in a prostate tumor xenograft model expressing high levels of constitutively active AR‐V7. Furthermore, mechanisms behind acquired cabazitaxel resistance were explored.

Methods: Mice were subcutaneously inoculated with 22Rv1 cells and treated with surgical castration (n = 7), abiraterone (n = 9), cabazitaxel (n = 6), castration plus abiraterone (n = 8), castration plus cabazitaxel (n = 11), or vehicle and/or sham operation (n = 23). Tumor growth was followed for about 2 months or to a volume of approximately 1000 mm3. Two cabazitaxel resistant cell lines; 22Rv1‐CabR1 and 22Rv1‐CabR2, were established from xenografts relapsing during cabazitaxel treatment. Differential gene expression between the cabazitaxel resistant and control 22Rv1 cells was examined by whole‐genome expression array analysis followed by immunoblotting, immunohistochemistry, and functional pathway analysis.

Results: Abiraterone treatment alone or in combination with surgical castration had no major effect on 22Rv1 tumor growth, while cabazitaxel significantly delayed and in some cases totally abolished 22Rv1 tumor growth on its own and in combination with surgical castration. The cabazitaxel resistant cell lines; 22Rv1‐CabR1 and 22Rv1‐CabR2, both showed upregulation of the ATP‐binding cassette sub‐family B member 1 (ABCB1) efflux pump. Treatment with ABCB1 inhibitor elacridar completely restored susceptibility to cabazitaxel, while treatment with AR‐antagonists bicalutamide and enzalutamide partly restored susceptibility to cabazitaxel in both cell lines. The cholesterol biosynthesis pathway was induced in the 22Rv1‐CabR2 cell line, which was confirmed by reduced sensitivity to simvastatin treatment.

Conclusions: Cabazitaxel efficiently inhibits prostate cancer growth despite the high expression of constitutively active AR‐V7. Acquired cabazitaxel resistance involving overexpression of efflux transporter ABCB1 can be reverted by bicalutamide or enzalutamide treatment, indicating the great clinical potential for combined treatment with cabazitaxel and anti‐androgens.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2019.
Nyckelord [en]
ABCB1, androgen receptor, cabazitaxel, cholesterol, prostate cancer, splice variant
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-167098DOI: 10.1002/pros.23935ISI: 000500369300001PubMedID: 31799745OAI: oai:DiVA.org:umu-167098DiVA, id: diva2:1384142
Forskningsfinansiär
Cancerfonden, CAN 2013/1324Cancerfonden, CAN 2018/863Vetenskapsrådet, 2018-02594Tillgänglig från: 2020-01-09 Skapad: 2020-01-09 Senast uppdaterad: 2020-01-09

Open Access i DiVA

fulltext(2503 kB)37 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2503 kBChecksumma SHA-512
5338f199b6de39b9ca375fb55733c50c9487529e9e056035bb1f91df03861ed5ea3bc6530356a388a2126984cab79272f0eb13b0e25701dcdc8ce5d93069cd14
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Bovinder Ylitalo, ErikThysell, ElinThellenberg-Karlsson, CamillaLundholm, MarieWidmark, AndersBergh, AndersJosefsson, AndreasBrattsand, MariaWikström, Pernilla

Sök vidare i DiVA

Av författaren/redaktören
Bovinder Ylitalo, ErikThysell, ElinThellenberg-Karlsson, CamillaLundholm, MarieWidmark, AndersBergh, AndersJosefsson, AndreasBrattsand, MariaWikström, Pernilla
Av organisationen
PatologiOnkologiWallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Urologi och andrologi
I samma tidskrift
The Prostate
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 37 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 200 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf